Advanced Cervical Cancer Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
In April 2025, Amgen announced a study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose ...
EconoTimes8d
AstraZeneca’s Imfinzi Gets US Approval for Bladder Cancer Treatment
AstraZenecas drug Imfinzi (NASDAQ: AZN) has received U.S. approval to treat adult patients with muscle-invasive bladder ...
Fierce Pharma8d
AstraZeneca bulks up Imfinzi's prowess with FDA nod in bladder cancer around surgery
AstraZeneca has secured another expansion of its Imfinzi for use in cancer patients before and after surgery. | Imfinzi is ...
CURE6d
Dive Into March 2025 FDA Approvals Across Cancer Subtypes
Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal ...
Business Wire8d
IMFINZI® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer
In the trial, 1,063 patients were randomized to receive IMFINZI plus neoadjuvant chemotherapy ... the concept of immunotherapy into dedicated clinical areas of high unmet medical need.
The Pharma Letter8d
AstraZeneca’s Imfinzi wins FDA nod for MIBC
Imfinzi (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant ...
Fierce Biotech11d
BioNTech shows off lung cancer survival data behind phase 3 push for red-hot bispecific
BioNTech has shown why it made small cell lung cancer (SCLC) a priority for its PD-L1xVEGF-A bispecific. | BioNTech has shown ...
Targeted Oncology4d
Behind Durvalumab's FDA Approval: NIAGARA Trial in MIBC
Matt Galsky, MD, discusses the phase 3 NIAGARA trial that led to the recent FDA approval of durvalumab in muscle-invasive ...
The Pharma Letter4d
Two new EU approvals for AstraZeneca
UK pharma major AstraZeneca (LSE: AZN) today reported extended approvals in Europe for two of its cancer drugs: Imfinzi ...
PharmiWeb8d
Imfinzi approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer
In the trial, 1,063 patients were randomised to receive Imfinzi plus neoadjuvant chemotherapy prior ... AstraZeneca is a pioneer in introducing the concept of immunotherapy into dedicated clinical ...
Yahoo Finance8d
IMFINZI® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer
Based on NIAGARA Phase III trial results which showed a 32% reduction ... March 31, 2025--(BUSINESS WIRE)--AstraZeneca’s IMFINZI ® (durvalumab) in combination with gemcitabine and cisplatin ...